Induction treatment with monoclonal antibodies for heart transplantation

Delgado, Juan; Vaqueriza, D; Sánchez, Verónica Adriana Galván; Escribano, Pilar; Ruiz-Cano, María J.; Renes, Emilio; Gómez-Sánchez, Miguel Ángel; Cortina, José M.; Calzada, Carlos Sáenz de la

doi:10.1016/j.trre.2010.10.002

Cited by 11 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the setting of induction (rather than rescue of acute rejection), recent results of a randomized trial of muromonab versus the chimeric anti-CD25 mAb basiliximab and retrospective analyses examining muromonab versus basiliximab in heart transplantation recipients suggest that targeting CD25, a component of the interleukin-2 receptor on activated T and B cells, confers similar antirejection efficacy but with lower complication rates. 45,46 In recent years, clinical evaluation of mAbs for cardiovascular indications has intensified outside the area of heart transplantation, including the prevention of thrombosis and treatment of hypercholesterolemia, as discussed below. Abciximab, which binds glycoprotein IIb/IIIa and prevents platelet adhesion to fibrinogen and corresponding platelet aggregation, significantly reduces the short-term reinfarction rate and mortality when used as adjunctive therapy for ST-segment-elevation myocardial infarction.…”

Section: Clinical Update In Cardiologymentioning

confidence: 99%

Evolution and Emergence of Therapeutic Monoclonal Antibodies

2013

View full text Add to dashboard Cite

Section: Clinical Update In Cardiologymentioning

confidence: 99%

Evolution and Emergence of Therapeutic Monoclonal Antibodies

2013

View full text Add to dashboard Cite

“…Both CD4 + and CD8 + T cells are implicated in IR/type 2 diabetes mellitus (T2DM), but the clinical usefulness of these observations is limited by risks that accompany T cell manipulation (7, 8). Known discrepancies between murine and human immune cell function further undermine translatability of studies highlighting critical roles for CD4 + Th1, Th2, Th17, regulatory T cells (Tregs) or CD8 + T cells in murine IR (1, 2, 6).…”

Section: Introductionmentioning

confidence: 99%

Th17 cytokines differentiate obesity from obesity‐associated type 2 diabetes and promote TNFα production

Cilfone

Belkina

et al. 2015

Obesity

114

115

View full text Add to dashboard Cite

Objective T cell inflammation plays pivotal roles in obesity-associated type 2 diabetes (T2DM). The identification of dominant sources of T cell inflammation in humans remains a significant gap in understanding disease pathogenesis. We hypothesized that cytokine profiles from circulating T cells identify T cell subsets and T cell cytokines that define T2DM-associated inflammation. Methods We used multiplex analyses to quantify T cell-associated cytokines in αCD3/αCD28-stimulated PBMCs, or B cell-depleted PBMCs, from subjects with T2DM or BMI-matched controls. We subjected cytokine measurements to multivariate (principal component and partial least squares) analyses. Flow cytometry detected intracellular TNFα in multiple immune cells subsets in the presence/absence of antibodies that neutralize T cell cytokines. Results T cell cytokines were generally higher in T2DM samples, but Th17 cytokines are specifically important for classifying individuals correctly as T2DM. Multivariate analyses indicated that B cells support Th17 inflammation in T2DM but not control samples, while monocytes supported Th17 inflammation regardless of T2DM status. Partial least squares regression analysis indicated that both Th17 and Th1 cytokines impact %HbA1c. Conclusions Among various T cell subsets, Th17 cells are major contributors to inflammation and hyperglycemia, and are uniquely supported by B cells in obesity-associated T2DM.

show abstract

“…Options for induction therapy include ATGs, anti-IL2 receptor antibodies, and anti-CD3 antibodies ( 16 ), all of which have been shown to significantly reduce acute rejection rates in the short-term perioperative setting ( 17 , 18 ). The 2021 Organ Procurement and Transplantation Network (OPTN) Report indicated that 67.5% of adult transplant patients were discharged on a triple therapy maintenance regimen consisting of tacrolimus, MMF, and corticosteroids, while the remaining 25.6% of patients were discharged on dual therapy (tacrolimus-MMF) ( 19 ).…”

Section: Perioperative Standard Pharmacological Therapy In Transplant...mentioning

confidence: 99%

Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions

Knoedler,

Dean,

Diatta

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Balancing the immune response after solid organ transplantation (SOT) and vascularized composite allotransplantation (VCA) remains an ongoing clinical challenge. While immunosuppressants can effectively reduce acute rejection rates following transplant surgery, some patients still experience recurrent acute rejection episodes, which in turn may progress to chronic rejection. Furthermore, these immunosuppressive regimens are associated with an increased risk of malignancies and metabolic disorders. Despite significant advancements in the field, these IS related side effects persist as clinical hurdles, emphasizing the need for innovative therapeutic strategies to improve transplant survival and longevity. Cellular therapy, a novel therapeutic approach, has emerged as a potential pathway to promote immune tolerance while minimizing systemic side-effects of standard IS regiments. Various cell types, including chimeric antigen receptor T cells (CAR-T), mesenchymal stromal cells (MSCs), regulatory myeloid cells (RMCs) and regulatory T cells (Tregs), offer unique immunomodulatory properties that may help achieve improved outcomes in transplant patients. This review aims to elucidate the role of cellular therapies, particularly MSCs, T cells, Tregs, RMCs, macrophages, and dendritic cells in SOT and VCA. We explore the immunological features of each cell type, their capacity for immune regulation, and the prospective advantages and obstacles linked to their application in transplant patients. An in-depth outline of the current state of the technology may help SOT and VCA providers refine their perioperative treatment strategies while laying the foundation for further trials that investigate cellular therapeutics in transplantation surgery.

show abstract

Induction treatment with monoclonal antibodies for heart transplantation

Cited by 11 publications

References 45 publications

Evolution and Emergence of Therapeutic Monoclonal Antibodies

Evolution and Emergence of Therapeutic Monoclonal Antibodies

Th17 cytokines differentiate obesity from obesity‐associated type 2 diabetes and promote TNFα production

Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions

Contact Info

Product

Resources

About